Tirzepatide + B12

Dual GLP-1/GIP weight management.

Tirzepatide is a dual GLP-1/GIP receptor agonist that provides powerful weight management through two complementary pathways, enhanced with B12.

How it works

Tirzepatide activates both GLP-1 and GIP receptors, providing a dual mechanism for appetite reduction, improved glucose metabolism, and enhanced fat utilization.

Benefits

• Dual-action weight management
• Superior appetite control
• Improved insulin sensitivity
• B12 metabolic support
• Once-weekly dosing

Dosing protocol

Start at 2.5mg weekly for 4 weeks, titrate up to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg as tolerated. Weekly subcutaneous injection.

Contraindications

• Personal or family history of thyroid cancer
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pancreatitis
• Severe GI disease
• Pregnancy

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality. Medications only issued when clinically appropriate after provider evaluation.